Belantamab mafodotin is under clinical development by GSK and currently in Phase I for Systemic Lupus Erythematosus.

The increased risks for arterial thrombotic events (ATE), venous thromboembolism (VTE), and all-cause mortality known to be ...

"Incomplete lupus" is a term used to describe a person who has some symptoms of lupus but not enough to make the diagnosis ...

Patients with SLE have a higher prevalence of primary headaches vs those with RA or pSS, but similar percentages were found ...

The prevalence of fibromyalgia is higher among patients with SLE vs the general population, adding to an already significant ...

Atherosclerosis progression was more than twice as common in younger people with systemic lupus erythematosus (SLE) than in ...

A new study explored the potential of IncRNA CASC2 and miR-155 levels as non-invasive diagnostic biomarkers for systemic lupus erythematosus (SLE) and lupus nephritis (LN). Previous studies have found ...

The link between lupus and bipolar disorder is complex and can lead to misdiagnosis. Learn how to recognize the symptoms of ...

In a new study, the drug, deucravacitinib, proved to be a safe and more effective treatment for cutaneous lupus erythematosus ...

Discover a study where results suggest that patients with cutaneous lupus erythematosus may benefit from increased vigilance ...

Pegtarazimod is under clinical development by ReAlta Life Sciences and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury.